The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it. It's not a ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

Despite uncertainties arising from new FDA policies around COVID-19 vaccines, Moderna has cleared the agency's desk with its ...

The FDA is implementing stricter guidance for the approval of COVID-19 vaccines, according to a paper published in The New England Journal of Medicine.

Moderna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a ...

A series of new revelations has come to light about the FDA's delay in granting full approval to Novavax's COVID-19 shot, thanks to recent reporting from the Wall Street Journal and STAT News.